HC Wainwright & Co. analyst Robert Burns downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral.
HC Wainwright & Co. Downgrades TCR2 Therapeutics to Neutral
HC Wainwright & Co. analyst Robert Burns downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral.
Related Posts
Where Steven Madden Stands With Analysts
Steven Madden (NASDAQ:SHOO) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Morgan Stanley Upgrades Verizon Communications to Overweight, Raises Price Target to $44
Morgan Stanley analyst Simon Flannery upgrades Verizon Communications (NYSE:VZ) from Equal-Weight to Overweight and raises the price target from $41 to $44.
Why Enterprise And Marketing Cloud Platform iClick Interactive Asia Shares Are Higher Today
iClick Interactive Asia Group Ltd (NASDAQ: ICLK) shares are trading higher by over 24% after the company penned a merger deal with